Zhengli Xu

机构：Peking University, Peking University People's Hospital, South China Institute of Collaborative Innovation · ORCID：0009-0006-6668-5294

发表论文 83 篇 · 总被引 1098 次 · h-index 19

代表论文

• Comparable survival outcomes in HLA-Matched and haploidentical hematopoietic stem cell transplantation for severe aplastic anemia patients aged 40–50: A CBMTR Registry-based propensity score matching analysis over the last decade (2025 · Cancer Letters · 被引 15)
• Mini-dose methotrexate combined with methylprednisolone for the initial treatment of acute GVHD: a multicentre, randomized trial (2024 · BMC Medicine · 被引 14)
• HLA haploidentical HSCT: from immune imbalance to a platform for immune homeostasis restoration (2025 · Immunity & Inflammation · 被引 10)
• CD8 + HLA-DR + CD27 + T cells define a population of naturally occurring regulatory precursors in humans (2025 · Science Advances · 被引 8)
• Clinical outcomes of three haploidentical transplantation protocols for hematologic malignancies based on data from the Chinese Bone Marrow Transplantation Registry Group (2024 · Haematologica · 被引 8)
• Randomized trial of anti-thymocyte globulin plus low-dose post-transplant cyclophosphamide to prevent graft-versus-host disease in haploidentical transplantation (2025 · Haematologica · 被引 7)